New Oligonucleotide Therapy Shows Promise for DMD

Preclinical studies published in PNAS show that supercharged bifunctional antisense oligonucleotides efficiently skip mutated exons and restore dystrophin expression in Duchenne muscular dystrophy models, according to findings from Nanjing Antisense Biopharm researcher Pengchao Feng and his team.

Bipartite Antisense Oligonucleotides Target Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked recessive progressive muscle condition primarily affecting boys. Mutations in the gene encoding the dystrophin protein cause muscle weakness and degeneration. According to the published study, conventional exon-skipping antisense oligonucleotides often lack the potency required for robust therapeutic outcomes, prompting the development of an advanced technique.

The research team developed bipartite antisense oligonucleotides featuring a short 5’-splice site decoy sequence that promotes efficient exon skipping. This tail is carried by the antisense portion to a target pre-messenger RNA. Once there, it interferes with the recognition of the exon’s 5′-splice site, markedly improving exon skipping compared to older designs without such tails.

Systemic Administration and Safety Profile in Animal Models

Testing in animal models demonstrated successful systemic delivery and functional recovery. According to the researchers, an 8-nucleotide tail attached to the 5′ end of antisense sequences targeting DMD exon 51 robustly enhanced skipping in both skeletal and cardiac muscles, restoring dystrophin expression in genetically modified mice.

Furthermore, testing in cynomolgus monkey models yielded a favorable safety profile alongside marked exon skipping. “We confirmed 5D-ASO’s wide applicability with diverse genes and exons,” the research team reported, highlighting the platform’s potential for future clinical translation.

Evolution of Antisense Oligonucleotide Therapeutics

Antisense technology has evolved significantly since developers began utilizing oligonucleotides to downregulate specific gene expression in the late 1970s, as reviewed in PMC literature. Early breakthroughs relied on molecules that activated RNaseH to destroy target RNA. However, manipulating alternative splicing requires a different approach: oligonucleotides must remain RNaseH inactive and access pre-mRNAs within cell nuclei to compete with splicing factors without destroying the transcript prematurely.

Despite these chemical advances—including 2′-O-methyl, morpholino, and peptide nucleic acid modifications—progress toward widespread clinical application has been slow. PMC records note that only a single antisense oligonucleotide compound, Vitravene, won FDA approval for cytomegalovirus-induced retinitis prior to recent clinical trials focusing on exon-skipping drugs for Duchenne muscular dystrophy.

Frequently Asked Questions

What is a bipartite antisense oligonucleotide?

It is a short, synthetic nucleic acid analog consisting of an antisense portion attached to a regulatory tail that recruits splicing suppressors to modify pre-mRNA processing.

How does the 5D-ASO technique improve Duchenne muscular dystrophy treatment?

According to the PNAS study, the short 5’-splice site decoy sequence enhances splicing repression, allowing for more efficient exon skipping and robust restoration of dystrophin expression in muscle tissues.

Are antisense oligonucleotide therapies currently approved for DMD?

Yes, conventional exon-skipping ASOs have gained regulatory approval for treating Duchenne muscular dystrophy, though researchers continue developing advanced bipartite designs to overcome potency limitations.